Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
In this phase 2 trial, sotorasib therapy led to a durable clinical benefit without new safety signals in patients with previously treated <i>KRAS</i> p.G12C-mutated NSCLC. (Fund...
Publications
2 shown<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma
Abstract KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups o...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 3,072
- Institution
- The University of Texas MD Anderson Cancer Center
External Links
Identifiers
- ORCID
- 0000-0002-4676-4503
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.